AbCellera to Present ABCL635 Phase 1/2 Data at TMS 2026 on Oct. 22

AbCellera plans to present Phase 1/2 ABCL635 data at TMS 2026 on Oct. 22, including safety, pharmacokinetics, pharmacodynamics and preliminary efficacy. The presentation will include new Phase 1 multiple ascending dose safety data and new Phase 2 patient-reported outcomes.